Stock Events

Stock Events

Verrica Pharmaceuticals 

€5.41
0
-€0.09-1.64% Thursday 13:31

Statistics

Day High
5.52
Day Low
5.41
52W High
7.18
52W Low
0.35
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q4 2025
Next
-0.61
-0.53
-0.46
-0.39
Expected EPS
-0.3871356892
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1NE0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AnaptysBio
ANAB
Mkt Cap1.69B
AnaptysBio, Inc. focuses on developing antibody-based therapies for dermatological conditions, directly competing with Verrica's dermatology products.
Journey Medical
DERM
Mkt Cap171.27M
Journey Medical Corporation is directly involved in dermatology, marketing products that compete in the same space as Verrica's treatments for skin conditions.
Bausch Health Companies
BHC
Mkt Cap2.1B
Bausch Health Companies Inc. has a broad portfolio in dermatology, offering products that compete with Verrica's skin treatment solutions.
Pfizer
PFE
Mkt Cap153.59B
Pfizer Inc. has a diverse range of healthcare products, including treatments for dermatological conditions, making it a competitor in the dermatology market.
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, offers products for skin health, competing in the same market as Verrica.
Abbvie
ABBV
Mkt Cap351.47B
AbbVie Inc. has a strong presence in dermatology with its Humira product and others, competing in the same therapeutic areas as Verrica.
AMGEN
AMGN
Mkt Cap185.74B
Amgen Inc. develops treatments for various conditions, including skin diseases, making it a competitor in the dermatology space.
GSK
GSK
Mkt Cap108.66B
GlaxoSmithKline plc has a portfolio that includes treatments for skin conditions, competing with Verrica's dermatological products.
Merck
MRK
Mkt Cap276.38B
Merck & Co., Inc. offers a range of healthcare products, including treatments for skin conditions, making it a competitor in the dermatology market.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals, Inc. is known for its innovative treatments in dermatology, directly competing with Verrica Pharmaceuticals in the development of skin disease treatments.

About

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Show more...
CEO
Dr. Jayson M. Rieger M.B.A., Ph.D.
Employees
71
Country
United States
ISIN
US92511W2070

Listings

F
DE
1NE0.F
XNAS
US
VRCA
STU
DE
1NE0.STU
MU
DE
1NE0.MU

0 Comments

Share your thoughts

FAQ

What is Verrica Pharmaceuticals stock price today?▼
The current price of 1NE0.STU is €5.41 EUR — it has decreased by -1.64% in the past 24 hours. Watch Verrica Pharmaceuticals stock price performance more closely on the chart.
What is Verrica Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Verrica Pharmaceuticals stocks are traded under the ticker 1NE0.STU.
Is Verrica Pharmaceuticals stock price growing?▼
1NE0.STU stock has risen by +0.37% compared to the previous week, the month change is a -6.88% fall, over the last year Verrica Pharmaceuticals has showed a +1,213.11% increase.
When is the next Verrica Pharmaceuticals earnings date?▼
Verrica Pharmaceuticals is going to release the next earnings report on May 12, 2026.
What were Verrica Pharmaceuticals earnings last quarter?▼
1NE0.STU earnings for the last quarter are -0.49 EUR per share, whereas the estimation was -0.61 EUR resulting in a +18.86% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Verrica Pharmaceuticals have?▼
As of May 03, 2026, the company has 71 employees.
In which sector is Verrica Pharmaceuticals located?▼
Verrica Pharmaceuticals operates in the Health & Wellness sector.
When did Verrica Pharmaceuticals complete a stock split?▼
Verrica Pharmaceuticals has not had any recent stock splits.
Where is Verrica Pharmaceuticals headquartered?▼
Verrica Pharmaceuticals is headquartered in West Chester, United States.